successfully accomplishing a variety of pressing tasks. Given similar numbers of workers, environmental conditions, and need, newly founded colonies built comb faster, foraged more, and stored greater amounts of food when their work forces were comprised of many genetically distinct patrilines. Initial differences in labor productivity amplified growth rates over time and led to dramatic fitness gains for genetically diverse colonies (i.e., production of drones, colony growth, and survival). Thus, we expect intense selection favoring polyandry because intracolonial genetic diversity improves the productivity of the work force and increases colony fitness during the risky process of colony founding.
Higher collective productivity of genetically diverse colonies may be rooted in a broader or more sensitive response from worker populations to changing conditions. The probability that a worker will engage in a task has been linked repeatedly to genotype [e.g. (5, 8, 19) ]. Consequently, colonies with multiple patrilines would be expected to have worker populations that are able to respond to a broad range of taskspecific stimuli and, as a group, should be able to provide appropriate, incremental responses to changes in these stimuli (5) . The observation that intracolonial genetic diversity improved productivity in colonies is consistent with predictions made by models of division of labor that rely on genotypic differences in response thresholds among workers (20) . Nevertheless, the extent to which genetically uniform colonies lagged behind genetically diverse colonies in the early stages of colony development was surprising, considering that colonies initially lacked comb and food reserves, and presumably, stimuli reflecting these needs could not have been greater. Actual response thresholds of workers are not well documented (20) , and it is difficult to know how they are related to the productivity of individuals and the colony as a whole. For example, workers may vary genetically in the rate at which they perform a task once their response threshold is reached or they may not be "good" at tasks for which they have high thresholds (i.e., they lack physiological apparatuses or experience). Alternatively, thresholds may be so high for some tasks that behaviors are effectively missing from a worker's repertoire, thus multiple patrilines would contribute to the diversity of labor in a colony, rather than division of labor among workers.
A key advantage of intracolonial genetic diversity was revealed during infrequent periods when food resources were plentiful (~33 days during our study). Genetically diverse colonies gained weight at rates that far exceeded those of genetically uniform colonies (Fig. 3) , whose sluggish foraging rates suggest that intracolonial genetic diversity enhances the discovery and exploitation of food resources by work forces, especially during periods when resources become suddenly and abundantly available. Intracolonial genetic diversity would result in more rapid mobilization of forager work forces if, by broadening the range of response thresholds in colonies, it increased the probability of having sufficient workers functioning as foragers and/or broadened the range of conditions over which foragers inspected, scouted, recruited to or were recruited/reactivated to food resources. Selection for polyandry would be strong if the genetic diversity that it bestows on colonies enhances the sophisticated mechanisms of honey bees for recruiting nest mates to food. Because successful colony founding by honey bees depends so heavily on rallying foragers and the swift accumulation of resources, this could explain, in concert with other benefits unrelated to worker productivity (15, 21) , the widespread occurrence of extreme polyandry in all honey bee species.
1 John E. Allen, 1 Lioudmila A. Zaslavskaia, 1 ‡ Gavin MacBeath 1 § PDZ domains have long been thought to cluster into discrete functional classes defined by their peptide-binding preferences. We used protein microarrays and quantitative fluorescence polarization to characterize the binding selectivity of 157 mouse PDZ domains with respect to 217 genome-encoded peptides. We then trained a multidomain selectivity model to predict PDZ domain-peptide interactions across the mouse proteome with an accuracy that exceeds many large-scale, experimental investigations of protein-protein interactions. Contrary to the current paradigm, PDZ domains do not fall into discrete classes; instead, they are evenly distributed throughout selectivity space, which suggests that they have been optimized across the proteome to minimize cross-reactivity. We predict that focusing on families of interaction domains, which facilitates the integration of experimentation and modeling, will play an increasingly important role in future investigations of protein function.
E ukaryotic proteins are modular by nature, comprising both interaction and catalytic domains (1, 2) . One of the most frequently encountered interaction domains, the PDZ domain, mediates protein-protein interactions by binding to the C termini of its target proteins (3) (4) (5) (6) . Previous studies of peptide-binding selectivity have placed PDZ domains into discrete functional categories: Class I domains recognize the consensus sequence Ser/Thr-X-y-COOH, where X is any amino acid and y is hydrophobic; class II domains prefer y-X-y-COOH; and class III domains prefer Asp/Glu-X-y-COOH (5, 7). More recent information has suggested that these designations are too restrictive and so additional classes have been proposed (8, 9) . The idea that domains fall into discrete categories, however, raises questions about functional overlap: Domains within the same class are more likely to cross-react with each other's ligands. To resolve this issue, we characterized and modeled PDZ domain selectivity on a genome-wide scale.
We began by cloning, expressing, and purifying most of the known PDZ domains encoded in the mouse genome (10) (11) (12) (table S1) . Soluble protein of the correct molecular weight was obtained for 157 PDZ domains ( fig. S1 ). Whereas previous efforts to characterize the selectivity of PDZ domains have relied on collections of peptides with randomized sequences (7, 9, 13, 14) , our goal was to focus on genome-encoded sequences. We therefore synthesized and purified fluorescently labeled peptides derived from the 10 C-terminal residues of mouse proteins. In total, we synthesized 217 such peptides, which we termed our "training set" (table S2) (15) . Although our training set is not guaranteed to contain ligands for every PDZ domain, it permitted us to obtain a broad view of binding selectivity.
To investigate biophysical interactions between the 157 well-behaved PDZ domains and each of the 217 fluorescent peptides, we devised a strategy that combines the throughput of protein microarrays and the fidelity of fluorescence polarization (FP) with predictive modeling (Fig.  1A) . Microarrays of PDZ domains were prepared within individual wells of microtiter plates and probed, in triplicate, with a 1 mM solution of each peptide (Fig. 1B) (16) . Interactions with a mean fluorescence that was at least three times the median fluorescence on the array were scored as "array positives" (17) . This process yielded 1301 putative interactions involving 127 PDZ domains. Little can be concluded about the 30 domains for which no array positives were found. For domains that bound at least one peptide, however, the inability to bind other peptides provides important information: These noninteractions were scored as "array negatives."
As with any high-throughput method, there are error rates associated with identifying both positives and negatives. To eliminate array false positives, we retested and quantified every array positive with a solution-phase FP assay (Fig. 1C) , which served as our "gold standard" (17) . By measuring FP at 12 concentrations of PDZ domain, we determined the dissociation constant (K d ) for each of the 1301 array positives (table S3). Interactions that showed saturation binding (18) with a K d < 100 mM were considered "positives"; those that did not were considered "negatives." On the basis of these criteria, 85 PDZ domains bound at least one peptide in the training set. Although our K d cutoff was high,~90% of the interactions had a K d < 50 mM, and~60% of interactions had a K d < 20 mM ( fig.  S2 ). In addition, FP assays revealed the falsenegative rate of the protein microarray assay to be 6.6% (19) .
To extract from our data the rules that govern the peptide-binding selectivity of PDZ domains, we built a model that predicts the PDZ domains to which a peptide will bind, given its sequence. Peptide recognition is often modeled with a position-specific scoring matrix (PSSM), Q = {q p,q }, where q p;q is defined as the probability of observing amino acid q at position p in the subset of peptides that bind to that domain (20) . This scoring approach is useful for predicting peptides that bind to a single domain, but it is not ideally suited to our purpose for two reasons. First, our peptide sequences are derived from the genome and thus are not random. Second, our goal is to learn how one domain differs from another, (i.e., how selectivity is achieved). This information is not captured in a traditional PSSM because peptide residues that contribute strongly to binding affinity, such as the C-terminal residue, dominate the model, even if they are not important in distinguishing one domain from another.
To construct a single model that includes many PDZ domains, we developed a variation of a PSSM in which a peptide is predicted to bind to PDZ domain i if
where ϕ is a binding score, A is an indicator of peptide sequence, ðA p;q ¼ 1 if the amino acid at position p of the peptide is q and A p;q ¼ 0 otherwise), and t i is a scoring threshold, specific to each domain. To ensure that our model focuses on PDZ domain selectivity, we constrained ∑ i q i;p;q to be 0 for every position p and every amino acid q. Thus, q i;p;q is positive if PDZ domain i prefers amino acid q at position p more than the other PDZ domains, negative if it prefers it less, and 0 if it has no bias relative to the other domains. To tailor the threshold appropriately for each domain, we defined t i to be the mth percentile of ϕ i 's for all of the peptides in our training set that bound to PDZ domain i. Empirically, we found that setting m = 5 provides a good balance between false-positive predictions and false-negative predictions. Because this model is designed to highlight selectivity across many members of a domain family, we refer to it as a multidomain selectivity model (MDSM).
Our model takes into account the five Cterminal residues of the peptide ligand: positions -4, -3, -2, -1, and 0. Even with 217 data points for each domain, there is insufficient information to train such a high-dimensional model. To avoid overfitting, we implemented a smoothing technique. If two PDZ domains bind a similar subset of peptides, it is reasonable to expect that their q p;q 's are also similar, unless the data suggest otherwise. Likewise, if two amino acids have similar physicochemical properties, it is reasonable to expect that their q i;p 's will be similar. Smoothing requires a quantitative measure of pairwise distance. With PDZ domains, distance was defined as the Hamming distance of their binding vectors across the training-set peptides. With amino acids, we relied on previously reported "z scales" to capture their physicochemical properties, where z 1 is considered a descriptor of hydrophilicity, z 2 is a descriptor of molecular weight and surface area, and z 3 is a descriptor of polarity and charge (21) . We reduced the equivalent degrees of freedom in our model by smoothing over PDZ domains and over amino acids with a Gaussian kernel during regression (22) .
We were able to model 74 of the 85 PDZ domains, which suggests that the majority of PDZ domains (87%) conform to the assumption that the contribution of each peptide position to selective binding is additive. Having trained the MDSM, we used it to predict false negatives in our microarray data (Fig. 1A) . Predicted array false negatives were assayed experimentally by quantitative FP, and the MDSM was retrained using the updated information. This cycle of prediction, experimentation, and retraining was performed three times. In total, we tested 303 predicted array false negatives, of which 133 (44%) were found to be positives, yielding a high-quality, quantitative interaction matrix for mouse PDZ domains ( Fig. 2A and table S3 ). Overall, we found that the average binding affinity of the array false negatives was slightly lower than that of the array true positives. The distributions of binding affinities, however, overlapped considerably ( fig. S3 ).
The refined model performs well on the updated data set, with a true-positive rate of 96% (it correctly identifies 515 of 536 FPconfirmed positives) and a false-positive rate of 15% (it predicts an interaction for 186 of 1229 FP-confirmed negatives) when m is set to 5 (Fig.  2B ). The parameters of the MDSM are depicted as a heat map in Fig. 2C and are provided in table S4. As anticipated, position 0 does not contribute strongly to discriminative binding, but the four other positions contribute substantially (Fig. 2C) .
To extract biophysical modules out of the resulting interaction network, we designed a modified version of the Markov cluster algorithm (23) , tailored to the special situation of a bipartite network (22) . The algorithm simulates a random walk on the graph and is based on the observation that random walks tend to be confined within "tight clusters" of nodes. The algorithm identified four tight clusters of PDZ domains and their binding partners (Fig. 2D ). For example, the claudins (tight junction proteins) cluster with ZO-1 and ZO-2, whereas the N-methyl-D-aspartic acid (NMDA) receptor subunit isoforms NMDAR2A and NMDAR2B, as well as several voltage-gated potassium channels, cluster with PSD-95, SAP-97, Magi-1, Magi-2, and Magi-3.
Encouraged by the close agreement of our model with the training-set data, we used the MDSM to predict to which proteins in the mouse proteome each of the 74 PDZ domains are able to bind. In total, we surveyed 31,302 peptide sequences corresponding to the C termini of all translated open reading frames (24). We have previously shown that our domain-based in vitro strategy faithfully captures~85% of the previously reported interactions involving PDZ domains (17) . We therefore provide these predictions (18,149 PDZ domain-peptide interactions) as supplemental information (table S5) to help guide future biological investigations (25). We note, however, that not all interactions that are observed in vitro necessarily occur in vivo.
To further assess the accuracy of our model, we selected a "test set" of 48 proteins from the mouse proteome that were predicted to be highly connected to PDZ domains (table S6). We synthesized fluorescently labeled peptides corresponding to their C termini and assayed them for binding to the 74 PDZ domains in our MDSM with the use of a single-point FP assay (26). These peptides were not included in the training set and so offer a stringent test of our model. In total, 493 new interactions and 3059 noninteractions were identified. Our model predicted 48% (237) of the new interactions and 88% (2680) of the noninteractions when m was set to 5 ( Fig. 2E) , with a truepositive/false-positive (TP/FP) ratio of 0.63 (237/379). The TP/FP ratio of our model predictions exceeds by a factor of more than 20 the TP/FP ratio of a Bayesian model that integrates information from two large-scale yeast twohybrid experiments and two large-scale in vivo pull-down experiments in Saccharomyces cerevisiae, while maintaining the same true-positive rate (27). We attribute the accuracy of our MDSM to its focus on a related family of domains, rather than on a broad collection of proteins with disparate properties. This argues strongly for a systematic but segmented effort to uncover proteinprotein interactions by focusing on families of interaction modules.
We also observed a positive correlation between the model output (ϕ i ) and binding affinity ( fig. S5 ). We found that smoothing over both PDZ domains and amino acids substantially contributes to the accuracy of the model, boosting the TP/FP ratio by 44% over the model constructed without smoothing, while maintaining the truepositive rate essentially the same (Fig. 2E) . Most of the effect was derived from smoothing over PDZ domains, but smoothing over amino acids was also beneficial. To exclude the possibility that the model performance was due to chance correlation, we performed a Y-randomization test (28) in which the interaction data were shuffled. The resulting receiver operating characteristic (ROC) curve was indistinguishable from the nodiscrimination line ( fig. S6 ), indicating the effectiveness of our training and test sets.
Having established that the model accurately captures information about the binding selectivity of PDZ domains, we asked which physicochemical properties each domain uses at each position to define its selectivity. For example, if we look at the amino acid preferences of Dlgh3 (1/1) at position -4, we find that the 20 q's are positively correlated with z 1 but are not correlated with z 2 or z 3 (Fig. 3A) . In contrast, z 2 , but not z 1 or z 3 , correlates with discriminative binding at position -4 for Magi-1 (4/6) (Fig. 3B) , whereas z 3 , but not z 1 or z 2 , correlates with discriminative binding at position -4 for MUPP1 (10/13) (Fig. 3C) . These three examples are extremes; in general, PDZ domains rely on all three z scales for discriminative binding. To capture this information for all PDZ domains at all positions, we constructed a correlation matrix between the model parameters and the first three z scales of amino acids (Fig.  3D) . Because the contribution to discriminative binding at position 0 is weak, we omitted this 
To understand the organization of peptidebinding selectivity on a global level, we deconvoluted the correlation matrix through singular-value decomposition and found that the distribution of PDZ domain binding preferences can be largely explained by three principal axes. The space defined by these axes can be thought of as "PDZ domain selectivity space." Each of the first two axes explains~30% of the variance in the correlation matrix, whereas the third axis explains~14% (Fig. 3E) . The first axis (Fig. 3F) can distinguish canonical class I PDZ domains, which are preferred by peptides with a small, hydrophilic residue at position -2, from canonical class II domains, which are preferred by peptides with a large, hydrophobic residue at posi- tion -2. Thus, the class I domains PSD-95 (1/3) and Shank3 (1/1) lie at the negative end of the first principal axis (Fig. 3G) , whereas the class II domains PDZ-RGS3 (1/1) and Grip1 (6/7) lie at the positive end. Erbin (1/1), which has been shown to bind both class I and class II peptides (28-31), lies between the two extremes. The second and third principal axes (Fig. 3F ) add further resolution. In particular, the third axis distinguishes class III domains, such as neuronal nitric oxide synthase (nNOS) (1/1) (preferred by peptides with a negatively charged residue at position -2), from the other PDZ domains. The closer a PDZ domain lies to the positive end of the third principal axis, the more it falls into the class III designation. There are, however, two important differences between the standard view of PDZ domain selectivity and the view that emerges from our broad investigation. First, positions -4, -3, -2, and -1 all contribute substantially to the definition of our three principal axes (Fig. 3F) . This implies that selectivity is derived from interactions throughout the binding pocket, whereas peptide library screens have shown that affinity is derived largely from the recognition of amino acids at positions -2 and 0 (7). Second, and more importantly, PDZ domains do not fall into discrete classes but instead lie on a continuum. Indeed, the canonical classes lie only in select portions of this continuum (i.e., at the extremes of the first and third principal axes). Moreover, the PDZ domains represented in our model are evenly distributed throughout selectivity space (Fig. 3G) . Zarrinpar et al. previously showed that the 23 Src homology 3 domains in S. cerevisiae are optimized to avoid cross-reactivity with the mitogen-activated protein kinase signaling protein Pbs2 (32). Here, we find on a much broader scale that a similar principle is in effect among mouse PDZ domains and their ligands. Although the selectivity of protein-protein interactions 
intrinsic selectivity of PDZ domains is tuned across the mouse proteome to minimize cross-reactivity.
Finally, we observed only a weak correlation (correlation coefficient r = 0.23) between the pairwise sequence divergence of PDZ domains and their distances in selectivity space (Fig. 3H) . Similarity at the overall sequence level is thus a poor predictor of PDZ domain function. This low correlation suggests that most of the sequence variation among PDZ domains is neutral with respect to peptide-binding selectivity and that only a subset of residues-presumably in the binding pocket of the PDZ domain-is responsible for the distribution of PDZ domains in selectivity space.
BioMart Here, we show that, in mice, less insulin receptor substrate-2 (Irs2) signaling throughout the body or just in the brain extended life span up to 18%. At 22 months of age, brain-specific Irs2 knockout mice were overweight, hyperinsulinemic, and glucose intolerant; however, compared with control mice, they were more active and displayed greater glucose oxidation, and during meals they displayed stable superoxide dismutase-2 concentrations in the hypothalamus. Thus, less Irs2 signaling in aging brains can promote healthy metabolism, attenuate meal-induced oxidative stress, and extend the life span of overweight and insulin-resistant mice.
R eaching old age in good health is not just good luck but the result of a favorable balance between hundreds of disease-causing and longevity-promoting genes; regardless, some common mechanisms that influence life span have emerged (1) . First, calorie restriction reliably increases animal longevity, and second, reduced insulin-like signaling extends life span in Caenorhabditis elegans and Drosophila melanogaster (2, 3). Calorie restriction and reduced insulin-like signaling might be linked because fasting reduces the intensity and duration of insulin secretion required for glucose homeostasis, and reduced insulin-like signaling promotes the expression of antioxidant enzymes that are associated with longevity (3) (4) (5) . Adapting these principles to humans is challenging because calorie restriction is difficult and because reduced insulin-like signaling can be associated with small stature, metabolic disease, and diabetes.
Insulin and insulin-like growth factor-1 (IGF1) bind to receptors on the surface of all cells that phosphorylate tyrosyl residues on the insulin receptor substrates (IRSs)-chico in Drosophila and Irs1, -2, -3, and -4 in mammals. This signaling cascade activates the phosphoinositide-3-kinase (Pik3C) and the thymoma viral proto-oncogene Akt, which regulates many cellular processes, including the inactivation of forkhead box O1 (FoxO1) transcription factor (6) . Reduced chico expression decreases brain and body growth while increasing life span up to 50%, which is related to the increased activity of dFOXO in Drosophila (7, 8) . In mice, the deletion of Irs1 reduces body growth and causes hyperinsulinemia, whereas the deletion of Irs2 Our study centered on a set of observations suggesting that the Wnt family of proteins could bind to klotho, a protein whose absence has been linked to an accelerated aging phenotype in mice. Genetic evidence suggests that alleles of klotho are also associated with variation in human longevity (1) . Nonetheless, we agree with Miller that considerable care must be taken when using the existing accelerated aging models as an indication of the normal aging process. Our opinion is that studying models of rapid aging will be useful in teasing out the underlying mechanisms of how we age, although we understand that Miller does not share that opinion. Hopefully, we will all live long enough to find out who is right.
HONGJUN LIU AND TOREN FINKEL
Cardiology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892, USA. Replicating Genome-Wide Association Studies GENOME-WIDE ASSOCIATION STUDIES PROMISE to significantly expand our knowledge of host control of deadly pathogens. Lurking in the background of these studies, however, is a serious methodologic issue. Individuals who participate in the cohorts used in genome-wide association studies are often ethnically and racially different from their fellow citizens who do not participate in these studies (1); more important, they are markedly different from the populations of developing countries with the highest burdens of infectious diseases.
The Report "A whole-genome association study of major determinants for host control of HIV-1" (J. Fellay et al., 17 August, p. 944) demonstrates how much can be learned from the study of a highly motivated, largely European cohort. Unfortunately, rather than suggesting that readers strive to replicate the study findings in different populations, J. Fellay et al. instead proceed directly to discussion of "directions for therapeutic intervention" and "urgency in carrying out similar studies for other infectious diseases."
In rushing these issues, the authors overlook several important points. Similar studies conducted in different geographic regions may fail to find the same associations, and may even find different associations. The highly polymorphic nature of human MHC, different pathogen strains, or gene-environment interactions could all result in variability of associations across populations in different regions. In some cases, such as the CCR5-∆32 mutant allele, genetic associations specific to geographic region may indeed aid drug or vaccine target discovery (2). However, a premature focus of financial and intellectual resources on a few specific alleles may throw out the baby for the bathwater. 
Response
WE RECENTLY REPORTED THAT THREE POLYmorphisms significantly influence host response to HIV-1. Two of these polymorphisms associate with viral load during the asymptomatic set point period, and the third associates with a measure of HIV-1 disease progression.
Kuniholm raises the question of whether the associations could be "replicated" in other geographic regions and suggests that it would have been preferable to evaluate this rather than moving to practical applications of the findings.
Our original study included samples from multiple European populations, both north and south; the effects observed cannot be viewed as the result of a specific cohort or geographic region within Europe. In the original study, we also replicated all three discoveries in a fully independent set of samples.
Kuniholm is correct that genetic effects are sometimes observed in some population groups and not others. The current consensus view is that when a polymorphism is present in different geographic regions, it tends to have a similar effect, but causal variants do vary in frequency among different groups (1, 2) . Indeed, one of our associations is known to be rare or absent in some geographic regions. Absence of a relevant genetic variant in a particular population does not in itself limit the applicability of new knowledge: The example of the CCR5-∆32 variant illustrates this point by demonstrating that a medication of universal use can indeed be developed on the basis of genetic information from one human population. The question of the geographic distribution of causal polymorphisms is an important one, but it is separate from the question of whether the polymorphisms have important clinical effects in the groups under study. Indeed, we are currently expanding our study to include multiple cohorts from the United States and from Africa.
DAVID B. GOLDSTEIN

A Measure of Respect for Translational Research
IT WAS A PLEASANT SURPRISE TO SEE A SPECIAL feature ("Careers in translational research," 17 August, p. 966) in Science focusing on translational research and its opportunities, risks, and challenges. In their respective articles, S. Carpenter (p. 966) and K. Garber (p. 968) highlight the concerns that translational researchers have about not being able to satisfy traditional measures of scientific success, including number of publications and impact factors. This apprehension is well founded. More worrisome is the scenario in which the onus is placed on the members of the translational community to prove their worth. I think it is too much. Measures of basic research productivity are well established, but the same is not true for translational research. I agree with Wu's advice (p. 967) to "go with what you passionately care about, because it's a long row, no matter how you hoe it," but I also sympathize with June's lament (p. 969): "I have seen several instances since I've been at [Penn] where promising translational researchers had to go back and just do basic research in order to assure their promotion."
It is time to think seriously about how to develop criteria for quantitatively evaluating 
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on March 29, 2011 www.sciencemag.org translational work. "Bench-to-bedside" and "lab-to-clinic" research will otherwise suffer from a perennial problem of lack of recognition. Considering the risk of failure in translational research, we need to be openminded and adopt measures that focus not only on success but on honest effort. Achievements such as partnering, patents, clinical trials, and drug screening should be considered on par with publications for assessment and promotion. Successes in translational efforts should be provided with "impact factors" commensurate with the volume of work, time taken, or importance in terms of clinical or pharmacological utility.
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